Breaks Categories: News

ThursdayJul 27, 2017 9:23 am

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Research Published in the European Journal of Pain

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the publication of company-sponsored research in the European Journal of Pain. The article, titled ‘Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation’, highlights results from a study co-sponsored by InMed and the MITACS Elevate Postdoctoral Fellowship Program. “Developing a topically-applied product that can provide localized relief of chronic and/or acute severe pain, without central side effects, remains one of the 'holy grails' in the field of analgesia,” Dr. Sazzad Hossain, chief scientific officer of InMed, stated in the news release. “This…

Continue Reading

WednesdayJul 26, 2017 2:46 pm

NetworkNewsBreaks – InfoSonics Corp. (NASDAQ: IFON) Enters Definitive Merger Agreement to Acquire Cooltech Holding Corp.; Shares Higher

InfoSonics (NASDAQ: IFON) is trading 39% higher following early news of the company’s definitive merger agreement to acquire Cooltech Holding Corp. Cooltech is an Apple licensed partner and reseller that operates as a vertically integrated company combining a distribution business with a growing retail footprint under its OneClick branded stores. Cooltech will become a wholly owned subsidiary of InfoSonics in exchange for 62.5 million shares of InfoSonics common stock upon closing of the merger transaction. The company expects to close the transaction in the fourth quarter of 2017, subject to approval by InfoSonics’ shareholders. "We believe this merger represents an…

Continue Reading

WednesdayJul 26, 2017 1:01 pm

NetworkNewsBreaks – Argos Therapeutics, Inc. (NASDAQ: ARGS) Shares Soar on Immunogenicity Data from AGS-004 in HIV Program

Argos Therapeutics (NASDAQ: ARGS) shares jumped more than 17% this morning on the company’s report of immunogenicity data from a study of AGS-004 dendritic cell therapy in patients treated during acute HIV infection. AGS-004 is an autologous cell therapy manufactured using the Arcelis® precision immunotherapy technology platform. During the open label study conducted at the University of North Carolina and Duke University, AGS-004 was produced on an individual basis for each patient. The study achieved its primary endpoint, with all six patients demonstrating a positive immune response. These data were recently published in the Journal of AIDS Research and Human…

Continue Reading

WednesdayJul 26, 2017 9:55 am

NetworkNewsBreaks – Net Element’s (NASDAQ: NETE) PayOnline Announces Support for iDEAL

Global financial technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE), through its PayOnline subsidiary, this morning announced that it has added support for iDEAL (https://www.ideal.nl/en/), a popular e-commerce payment system and market share leader in the Netherlands. Per a report by Thuiswinkel.org and the Ecommerce Foundation, the iDEAL payment system is currently the most widely used method of online payments in the Netherlands, accounting for roughly 54 percent of all Dutch online payments across over 220 million transactions as of 2015. This market presence is particularly noteworthy as online spending in the Netherlands continues to grow. In 2016,…

Continue Reading

WednesdayJul 26, 2017 9:23 am

NetworkNewsBreaks – ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Issues Update on Construction and Expansion Activities

ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) this morning provided an update on its construction and expansion timelines for its Vanluven and Kimmett facilities, both of which are located in Napanee, Ontario. Per the update, ABcann’s plans to commence construction at its Kimmett facility in the third quarter of 2017 remain on schedule, and the previously announced plans for a 71,000 square foot Phase 1 project have been expanded to 100,000 square feet. Additionally, the company has initiated immediate expansion and construction efforts at its current production facility at Vanluven with the goal of doubling production capacity in order to…

Continue Reading

TuesdayJul 25, 2017 2:22 pm

NetworkNewsBreaks – Neuralstem, Inc. (NASDAQ: CUR) Shares Plunge on Top-line Phase 2 Data of NSI-189 for MDD

Shares of Neuralstem (NASDAQ: CUR) plummeted 57% following the company’s release of top-line data from its exploratory phase 2 clinical trial on the efficacy of NSI-189 for Major Depressive Disorder (MDD). The trial did not meet its primary efficacy endpoint of a statistically significant reduction in depression symptoms on the Montgomery-Asberg Depression Rating Scale (MADRS). The trial evaluated NSI-189 at 40 mg once daily and 40 mg twice daily compared to placebo. The 40 mg once daily dose was directionally positive on the MADRS. One of the trial's two secondary endpoints, the patient-rated Symptoms of Depression Questionnaire (SDQ), achieved statistical…

Continue Reading

TuesdayJul 25, 2017 12:02 pm

NetworkNewsBreaks – Flex Pharma, Inc.’s (NASDAQ: FLKS) FLX-787 Receives Fast Track Designation from FDA to Treat Severe ALS Cramps

Flex Pharma (NASDAQ: FLKS) shares are up 23% this morning on news that the company’s co-activator of TRPA1 and TRPV1, FLX-787, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to treat severe muscle cramps in patients with ALS. Currently, no treatments for this condition are approved in the U.S. “With Phase 2 clinical trials in both ALS and CMT expected to initiate this quarter in the US, FLX-787 will be amongst the most advanced, novel compounds in the clinic for these degenerative neurological diseases. The R&D team is focused on the execution of these…

Continue Reading

TuesdayJul 25, 2017 11:11 am

NetworkNewsBreaks – ORHub, Inc. (ORHB) Announces Launch of Neurosurgery Service Line

Health care software-as-a-service company ORHub, Inc. (OTC: ORHB) this morning announced the launch of its fourth service line, marking the company’s strategically planned entry point into neurosurgery. “We are excited to announce the new Neurosurgery service line so quickly after launching our previous modules,” Colt Melby, CEO of ORHub, stated in the news release. “The need for our software in the operating room is monumental, and we are aggressively working to expand our service line offerings to deliver our transformative software to key hospitals in major U.S. markets.” The company’s portfolio of service lines now includes software solutions for Spinal,…

Continue Reading

MondayJul 24, 2017 1:04 pm

NetworkNewsBreaks – Eltek (NASDAQ: ELTK) Shares Swell on $3M Order by Governmental Authority

Eltek (NASDAQ: ELTK) shares soared 79% toward its 52-week high of $1.33 this morning after the company said it has received an order of approximately $3 million from a governmental authority for a project comprising of manufacturing and procurement services. The project will take place during a period of two years measured by quarterly milestones the company is required to meet. At the end of the two years, the government authority will have the option to extend the project for an additional 12-month period. Eltek will receive quarterly payments subject to achieving the set milestones. "The selection of Eltek by…

Continue Reading

MondayJul 24, 2017 1:01 pm

NetworkNewsBreaks – Cytori Therapeutics, Inc. (NASDAQ: CYTX) Shares Plummet to New Low on Disappointing STAR Trial Results

Shares of Cytori Therapeutics (NASDAQ: CYTX) sunk to a new 52-week low of $0.45 following the company’s release of top-line preliminary data from its pivotal STAR trial of Habeo™ Cell Therapy in patients with scleroderma. Results show that statistical significance was not achieved in the primary endpoint, Cochin Hand Function Score (CHFS), or the secondary endpoint, Raynaud’s Condition Score. However, clinically meaningful efficacy trends were observed in both the efficacy endpoints. “We are disappointed that the study missed the primary and secondary endpoints. However, we are very encouraged by the trends toward improved hand function and scleroderma-related health status in…

Continue Reading